Genzyme/Sanofi gain Canadian OK for Lemtrada; US decision soon
This article was originally published in Scrip
Executive Summary
Sanofi US unit Genzyme won approval to market Lemtrada (alemtuzumab) in Canada as a therapy for adults with active relapsing/remitting multiple sclerosis (RRMS) who have had an inadequate response to interferon beta or other disease-modifying therapies.